Document Detail


Therapeutic potential of new second generation antipsychotics for major depressive disorder.
MedLine Citation:
PMID:  21105856     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
IMPORTANCE OF THE FIELD: Although a range of antidepressant medications are available, a substantial number of patients either do not respond adequately to these or are unable to tolerate their adverse effects. A treatment strategy that has gathered substantial empirical support is the use of second generation antipsychotic agents (SGAs) in combination with antidepressants for treatment-resistant nonpsychotic depression (TRD) or major depressive disorder (MDD) inadequately responsive to antidepressants. Aripiprazole, olanzapine and quetiapine each have indications that involve MDD. Growing evidence indicates that quetiapine, evaluated as the extended release formulation, is efficacious as monotherapy for nonpsychotic MDD.
AREAS COVERED IN THIS REVIEW: The pharmacological rationale for using SGAs in MDD, randomized, placebo-controlled data on individual SGAs in treatment of MDD and the emerging role of SGAs in the management of MDD.
WHAT THE READER WILL GAIN: A balanced overview of the evidence supporting the use of newer SGAs in MDD.
TAKE HOME MESSAGE: SGAs will have an increasingly important role in treatment of MDD, especially as augmentation agents. Further research is needed to clarify their efficacy and safety profiles, especially compared with other strategies for TRD.
Authors:
Susan L McElroy; Anna Guerdjikova; Nicole Mori; Paul E Keck
Related Documents :
6108796 - Noradrenergic function and depression, too much or too little?
19585106 - Short-term antidepressant treatment modulates amygdala response to happy faces.
19123456 - Treatment of major depressive disorder in the finnish general population.
20230736 - Clinical inquiries. what's best when a patient doesn't respond to the maximum dose of a...
15020006 - Tinker, tailor, soldier, patient: work attributes and depression disparities among youn...
17136986 - Eletrocardiographic monitoring in copd patients receiving tiotropium.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review    
Journal Detail:
Title:  Expert opinion on investigational drugs     Volume:  19     ISSN:  1744-7658     ISO Abbreviation:  Expert Opin Investig Drugs     Publication Date:  2010 Dec 
Date Detail:
Created Date:  2010-11-25     Completed Date:  2011-09-29     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  9434197     Medline TA:  Expert Opin Investig Drugs     Country:  England    
Other Details:
Languages:  eng     Pagination:  1527-44     Citation Subset:  IM    
Affiliation:
Lindner Center of HOPE, 4075 Old Western Row Road, Mason, Ohio 45040, USA. susan.mcelroy@lindnercenter.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antidepressive Agents, Second-Generation / chemistry,  therapeutic use*
Antipsychotic Agents / chemistry,  therapeutic use*
Depressive Disorder, Major / drug therapy*,  psychology*
Humans
Mianserin / analogs & derivatives,  chemistry,  therapeutic use
Piperazines / chemistry,  therapeutic use
Quinolones / chemistry,  therapeutic use
Randomized Controlled Trials as Topic / methods
Chemical
Reg. No./Substance:
0/Antidepressive Agents, Second-Generation; 0/Antipsychotic Agents; 0/Piperazines; 0/Quinolones; 24219-97-4/Mianserin; 61337-67-5/mirtazapine; 82VFR53I78/aripiprazole

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Perspective: does ranolazine have potential for the treatment of atrial fibrillation?
Next Document:  Dapagliflozin: more than just another oral glucose-lowering agent?